Peng Tao, Hu Zhao, Xia Qing, Jiang Bei, Li Xianhua, Yang Xiangdong
Department of Nephrology, Shandong University Qilu Hospital, Jinan, P. R. China.
Arzneimittelforschung. 2009;59(12):647-50. doi: 10.1055/s-0031-1296454.
To compare the renoprotective effects of the calcium channel blocker (CCB) benidipine (CAS 105979-17-7) and the angiotensin II receptor blocker (ARB) valsartan (CAS 137862-53-4) in primary hypertensive patients with proteinuria.
236 patients with primary hypertension were randomly divided into different groups and were administered either benidipine or valsartan. The alterations of the glomerular filtration rate (GFR) and proteinuria were compared between the different groups.
Valsartan could decrease the level of proteinuria significantly as compared with that in benidipine-treated hypertensive patients with proteinuria at levels <1 g/24 h (P < 0.01). There was no significant difference of the effects of benidipine and valsartan on proteinuria reduction in hypertensive patients with proteinuria at levels 1-3 g/24 h. There was no significant difference of the effects of benidipine and valsartan on GFR in benidipine- and valsartan-treated patients.
The results showed that valsartan was more effective in decreasing the levels of proteinuria in hypertensive patients with proteinuria at an early stage of nephropathy. The renoprotective effects of benidipine and valsartan in primary hypertensive patients with proteinuria were similar.
比较钙通道阻滞剂（CCB）贝尼地平（化学物质登记号105979-17-7）与血管紧张素II受体阻滞剂（ARB）缬沙坦（化学物质登记号137862-53-4）对原发性高血压合并蛋白尿患者的肾脏保护作用。
将236例原发性高血压患者随机分组，分别给予贝尼地平或缬沙坦治疗。比较不同组间肾小球滤过率（GFR）和蛋白尿的变化。
与贝尼地平治疗的蛋白尿水平<1g/24h的高血压患者相比，缬沙坦可显著降低蛋白尿水平（P<0.01）。对于蛋白尿水平为1-3g/24h的高血压患者，贝尼地平和缬沙坦在降低蛋白尿方面的效果无显著差异。在接受贝尼地平和缬沙坦治疗的患者中，二者对GFR的影响无显著差异。
结果表明，在肾病早期，缬沙坦在降低高血压合并蛋白尿患者的蛋白尿水平方面更有效。贝尼地平和缬沙坦对原发性高血压合并蛋白尿患者的肾脏保护作用相似。
